However, the role of MHC class I is critical, as various cancer types have evolved to evade T cell response by downregulating MHC class I expression [58], which provide NK cells with a unique attribute that can be leveraged when considering treatment approaches, particularly for tumors that are characterized by resistance to current antitumor CD8 + T cell therapies [59, 60]. The gene discussed is CD8A; the disease is cancer.